应对治疗挑战:沃里康纳的药理动力学和CYP2C19遗传多态性-A病例报告和文献综述
Sadaf Ahmer1, Jessica Bui1,2, Pirathaban Sivabalan3
1Department of Infectious Diseases, Royal North Shore Hospital, St Leonards, NSW, Australia.
British journal of clinical pharmacology
|October 31, 2025
概括
在免疫功能低下的患者中,Scedosporium apiospermum感染可能因影响药物代谢的遗传变异而难以用voriconazole治疗. 药物遗传学测试揭示了一种快速代谢基因型,导致治疗次的沃里康纳水平和治疗失败.
科学领域:
- 医学真菌学 医学真菌学
- 药物基因组学 药物基因组学
- 移植 传染病 移植 传染病
背景情况:
- 斯基多斯波里亚 (Scedosporium apiospermum) 是一种机会性真菌病原体,在免疫功能低下的人群中引起感染.
- 沃里科纳是一种一线抗真菌药物,但其疗效受到复杂的药理动力学和患者间变异性的限制.
- CYP450 (CYP2C19) 酶多态性显著影响伏利康纳的新陈代谢,导致药物水平变化和潜在的毒性.
研究的目的:
- 在移植接受者中报告Scedosporium apiospermum mycetoma的病例.
- 调查导致治疗次级沃里康纳水平的药理动力学和药理遗传学因素.
- 突出药物基因组测试在优化抗真菌治疗中的作用.
主要方法:
- 一个患有Scedosporium apiospermum mycetoma的移植患者的病例介绍.
- 手术切除瘤. 的手术切除.
- 启动沃里康纳治疗与治疗药物监测.
- 药物动力学分析以确定沃里科纳的半衰期.
- 药物遗传测试以确定CYP2C19的基因型.
主要成果:
- 尽管调整了剂量,但患者的血清水平持续低于治疗水平.
- 药物动力学分析显示,沃里康纳的半衰期缩短.
- 药物遗传学测试发现了一个CYP2C19 *1/*17基因型,表明快速代谢体的表型.
- 加快药物代谢导致血清水平降低,治疗失败的风险增加.
结论:
- CYP2C19基因型显著影响伏利康纳的新陈代谢,快速代谢者经历的药物暴露较低.
- 药物遗传学和药物动力学测试是优化伏利可纳治疗和预测治疗结果的宝贵工具.
- 应考虑与CYP2C19代谢无关的替代性抗真菌药物 (伊萨夫康纳,脂质体安福特里辛B,波萨康纳).
- 将药物基因组测试与治疗药物监测相结合,可以加强复杂病例的个性化抗真菌治疗.
关键词:
在CYP2C19的多态化中.斯基多斯波里亚亚亚皮奥斯珀姆 (Scedosporium apiospermum) 是一种精子.抗真菌疗法是一种抗真菌疗法.免疫功能低下的患者.药物遗传学 药物遗传学药物动力学 药物动力学沃里康纳 (Voriconazole) 是一种一种更多相关视频
相关概念视频
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
192
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
192
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
245
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
245
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
624
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
624
Pharmacokinetics: Overview
8.9K
Pharmacokinetics is a scientific discipline that focuses on the journey of a drug within the body, encompassing four key stages: absorption, distribution, metabolism, and elimination. The first stage, absorption, involves the drug's transfer into the bloodstream. Several factors dictate the extent and speed of this process. For example, the liver often metabolizes oral drugs before they reach systemic circulation, leading to only partial absorption. In contrast, intravenous (IV)...
8.9K
Pharmacokinetics: Drug–Drug Interactions
336
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
336
Pharmacokinetics in Pediatric Patients: Drug Metabolism
185
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
185


